Genome editing using the CRISPR/Cas9 system and its application in haematology

[1]      Levine AJ. Virus vector-mediated gene transfer. Microbiol Sci 1987;4(8):245–250.

[2]      Naldini L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med 2019;11(3):E9958.

[3]      Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4(5):346–358.

[4]      Pâques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 1999;63(2):349–404.

[5]      Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003;300(5620):763.

[6]      Stoddard BL. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 2011;19(1):7–15.

[7]      Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 1996;93(3):1156–1160.

[8]      Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011;333(6051):1843–1846.

[9]      Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier EA. programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337(6096):816–821.

[10]    Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012;109(39):E2579-E2586.

[11]    Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339(6121):819–823.

[12]    Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 2005;60(2):174–182.

[13]    Barrangou R, Marraffini LA. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell 2014;54(2):234–244.

[14]    Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Arch Dis Child Educ Pract Ed 2016;101(4):213–215.

[15]    Liu J-J, Orlova N, Oakes BL, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature 2019;566(7743):218–223.

[16]    Murugan K, Babu K, Sundaresan R, Rajan R, Sashital DG. The revolution continues: Newly discovered systems expand the CRISPR-Cas toolkit. Mol Cell 2017;68(1):15–25.

[17]    Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 2017;18(8):495–506.

[18]    Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Ann Rev Genet 2010;44(1):113–139.

[19]    Salsman J, Dellaire G. Precision genome editing in the CRISPR era. Biochem Cell Biol 2017;95(2):187–201.

[20]    Ran FA, Hsu PD, Lin C-Y, et al. Double nicking by RNA-guided CRISPR-Cas9 for enhanced genome editing specificity. Cell 2013;154(6):1380–1389.

[21]    Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. Gene 2017;599:1–18.

[22]    González-Romero E, Martínez-Valiente C, García-Ruiz C, Vázquez-Manrique RP, Cervera J, Sanjuan-Pla A. CRISPR to fix bad blood: a new tool in basic and clinical hematology. Haematologica 2019;104(5):881–893.

[23]    Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153(4):910–918.

[24]    Gundry MC, Brunetti L, Lin A, et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep 2016;17(5):1453–1461.

[25]    Bauer DE, Canver MC, Smith EC, et al. Crispr-Cas9 saturating mutagenesis reveals an Achilles heel in the BCL11A erythroid enhancer for fetal hemoglobin induction (by genome editing). Blood 2015;126(23):638.

[26]    Eldridge L, Zhang L, Ye Z. Defining the role of a GATA-2 enhancer during hematopoietic differentiation of human iPSCs. Blood 2017;130(Suppl 1):4939.

[27]    Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1(2):157–162.

[28]    Reimer J, Knöß S, Labuhn M, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica 2017;102(9):1558–1566.

[29]    Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez-Perales S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR–Cas9 system. Nat Commun 2014;5(1):3964.

[30]    Rathe SK, Moriarity BS, Stoltenberg CB, et al. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Sci Rep 2015;4(1):6048.

[31]    Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 2015;33(6):661–667.

[32]    Casanova J-L, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med 2014;211(11):2137–2149.

[33]    Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 2017;356(6336):438–442.

[34]    Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 2018;360(6387):436–439.

[35]    Hajian R, Balderston S, Tran T, et al. Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor. Nat Biomed Eng 2019;3(6):427–437.

[36]    Norkin M, Wingard JR. Recent advances in hematopoietic stem cell transplantation. F1000Research 2017;6:870.

[37]    Badat M, Davies J. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017;376(21):2093–2094.

[38]    Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010;467(7313):318–322.

[39]    Fischer A, Hacein-Bey Abina S, Touzot F, Cavazzana M. Gene therapy for primary immunodeficiencies. Clin Genet 2015;88(6):507–515.

[40]    Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector–mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357–2365.

[41]    Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem cells. Curr Opin Hematol 2017;24(6):481–488.

[42]    Huang X, Wang Y, Yan W, et al. Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells 2015;33(5):1470–1479.

[43]    Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014;24(9):1526–1533.

[44]    Skvarova Kramarzova K, Osborn M, Webber B, et al. CRISPR/Cas9-mediated correction of the FANCD1 gene in primary patient cells. Int J Mol Sci 2017;18(6):E1269.

[45]    Westin E, Devadasan D, Li C, Ding L, Townes TM, Goldman FD. CRISPR modification of induced pluripotent stem derived from Diamond-Blackfan anemia fibroblasts. Blood 2014;124(21):4804.

[46]    Chang K-H, Smith SE, Sullivan T, et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34 + hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev 2017;4:137–148.

[47]    Wu Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 2019;25:776–783.

[48]    A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. www.ClinicalTrials.gov.

[49]    A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia. www.ClinicalTrials.gov.

[50]    Biffi A. Hematopoietic stem cell gene therapy for storage disease: Current and new indications. Mol Ther 2017;25(5):1155–1162.

[51]    Moehle EA, Rock JM, Lee Y-L, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci 2007;104(9):3055–3060.

[52]    Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90(2):720–724.

[53]    Zhou H, Luo Y, Zhu S, et al. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer 2018;18(1):929.

[54]    Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Cripsr/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia. Blood 2015;126(23):4280.

[55]    Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T Cells (CAR-Ts): Combination or built-in CAR-T. Int J Mol Sci 2018;19(2):E340.

[56]    Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28(8):839–847.

[57]    Li G, Zhang X, Zhong C, et al. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep 2017;7(1):8943.

[58]    Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 2015;4:e264.

[59]    Zischewski J, Fischer R, Bortesi L. Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnol Adv 2017;35(1):95–104.

[60]    Wienert B, Wyman SK, Richardson CD, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science 2019;364(6437):286–289.

[61]    Ihry RJ, Worringer KA, Salick MR, et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat Med 2018;24(7):939–946.

[62]    Conti A, Di Micco R. p53 activation: a checkpoint for precision genome editing? Genome Med 2018;10(1):66.

[63]    Schenkwein D, Ylä-Herttuala S. Gene editing of human embryos with CRISPR/Cas9: great promise coupled with important caveats. Mol Ther 2018;26(3):659–660.

[64]    Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015;6(5):363–372.

[65]    Regalado A. EXCLUSIVE: Chinese scientists are creating CRISPR babies. MIT Technol Rev 2018;Nov 25.

[66]    Juengst ET, Henderson GE, Walker RL, et al. Is enhancement the price of prevention in human gene editing? Cris J 2018;1(6):351–354.